2024.07.18 Next Day Disclosure Return pdf-icon
2024.07.17 Next Day Disclosure Return pdf-icon
2024.07.16 Next Day Disclosure Return pdf-icon
2024.07.12 VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PROGRAM UNDER THE SHARE REPURCHASE MANDATE pdf-icon
2024.06.28 VOLUNTARY ANNOUNCEMENT - LAST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION pdf-icon
2024.06.28 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC ACCEPTED FOR E-POSTER PRESENTATION AT THE 29TH ANNUAL MEETING OF CSD pdf-icon
2024.06.27 OPERATIONAL UPDATE FOR THE FIRST QUARTER OF 2024 pdf-icon
2024.06.05 POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2024 pdf-icon
2024.05.31 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PRESENTED AT THE 13TH ADC pdf-icon
2024.05.30 VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS APPROVED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION pdf-icon
2024.04.30 VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR CU-40102 (TOPICAL FINASTERIDE SPRAY) IN HONG KONG, PRC pdf-icon
2024.04.30 VOLUNTARY ANNOUNCEMENT - A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY OBTAINED THE "DRUG MANUFACTURING CERTIFICATE" ISSUED BY THE JIANGSU MEDICAL PRODUCTS ADMINISTRATION pdf-icon
2024.04.26 FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 5 JUNE 2024 pdf-icon
2024.04.26 NOTICE OF ANNUAL GENERAL MEETING pdf-icon
2024.04.26 (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES (3) PROPOSED RE-APPOINTMENT OF AUDITOR AND (4) NOTICE OF ANNUAL GENERAL MEETING pdf-icon
2024.03.27 ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 pdf-icon
2024.03.27 VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS ACCEPTED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION pdf-icon
2024.03.18 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY IN FTSE GLOBAL EQUITY INDEX SERIES pdf-icon
2024.03.15 DATE OF BOARD MEETING pdf-icon
2024.02.29 OPERATIONAL UPDATE FOR THE YEAR ENDED 31 DECEMBER 2023 AND FOURTH QUARTER OF 2023 pdf-icon
2024.02.28 VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION IN CHINA pdf-icon
2024.02.20 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES pdf-icon
2024.01.31 VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-40102 (TOPICAL FINASTERIDE SPRAY) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION pdf-icon
2024.01.31 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA REACHED PRIMARY ENDPOINT pdf-icon
2024.01.03 VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION pdf-icon
2023.12.11 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIALS OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED AT THE 18TH CDA ANNUAL MEETING pdf-icon
2023.11.27 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION COMPLETED DATABASE LOCK pdf-icon
2023.11.06 OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 AND THIRD QUARTER OF 2023 pdf-icon
2023.11.02 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) IN CHINA REACHED PRIMARY ENDPOINT pdf-icon
2023.10.25 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION pdf-icon
2023.09.27 VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION pdf-icon
2023.09.07 VOLUNTARY ANNOUNCEMENT - REGISTRATIONAL PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) REACHED PRIMARY ENDPOINT pdf-icon
2023.09.05 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY IN THE LIST FOR SOUTHBOUND TRADING LINK UNDER THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT pdf-icon
2023.08.29 INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023 pdf-icon
2023.08.28 DISCLOSEABLE TRANSACTIONS - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS pdf-icon
2023.08.28 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) COMPLETED DATABASE LOCK pdf-icon
2023.08.23 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) pdf-icon
2023.08.18 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES pdf-icon
2023.08.17 DATE OF BOARD MEETING pdf-icon
2023.08.10 VOLUNTARY ANNOUNCEMENT - CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) HAS BEEN GRANTED PRIORITY REVIEW DESIGNATION BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION pdf-icon
2023.08.02 OPERATIONAL UPDATE FOR THE SECOND QUARTER AND FIRST HALF OF 2023 pdf-icon
2023.07.18 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) pdf-icon
2023.07.05 STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION pdf-icon
2023.06.09 LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS pdf-icon
2023.06.09 Terms of Reference for the Nomination Committee pdf-icon
2023.06.09 Terms of Reference for the Remuneration Committee pdf-icon
2023.06.09 Terms of Reference for the Audit Committee pdf-icon
2023.06.09 ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS pdf-icon
2023.05.31 GLOBAL OFFERING pdf-icon
2023.05.31 GREEN APPLICATION FORM pdf-icon
2023.05.31 GLOBAL OFFERING (Multi-Files) pdf-icon
2023.05.31 GLOBAL OFFERING pdf-icon